These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 35582379)

  • 1. EGFR/BRAF/MEK co-inhibition for EGFR-mutated lung adenocarcinoma patients with an acquired BRAF
    Zeng R; Luo L; Sun X; Bao Z; Du W; Dai R; Tang W; Gao B; Xiang Y
    Cancer Drug Resist; 2021; 4(4):1019-1027. PubMed ID: 35582379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promising response of dabrafenib, trametinib, and osimertinib combination therapy for concomitant BRAF and EGFR-TKI resistance mutations.
    Chimbangu CT; Ya Z; Xi L; Jiayue Z; Xiao M; Ying W; Xingxu Y; Liu X
    Anticancer Drugs; 2024 Jan; 35(1):109-115. PubMed ID: 37578745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case report: Dual dabrafenib and trametinib therapy for treating BRAF V600E mutated lung adenocarcinoma with BRCA2 germline mutation post multiline progression.
    Zhang H; Cong X; Yin J; Chen C; Liu Z
    Front Oncol; 2024; 14():1387388. PubMed ID: 38715777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful re-challenge of dabrafenib-trametinib combination therapy in advanced
    Xue Y; Ren Y; Yan B; Li Z; Huang C
    Ann Transl Med; 2022 Sep; 10(18):1029. PubMed ID: 36267742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting
    Aboubakar Nana F; Ocak S
    Pharmaceutics; 2021 Sep; 13(9):. PubMed ID: 34575554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF
    Facchinetti F; Lacroix L; Mezquita L; Scoazec JY; Loriot Y; Tselikas L; Gazzah A; Rouleau E; Adam J; Michiels S; Massard C; André F; Olaussen KA; Vassal G; Howarth K; Besse B; Soria JC; Friboulet L; Planchard D
    Eur J Cancer; 2020 Jun; 132():211-223. PubMed ID: 32388065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acquired BRAF N581S mutation mediated resistance to gefitinib and responded to dabrafenib plus trametinib.
    Liu Y; Zeng H; Wang K; Li Y; Tian P; Li W
    Lung Cancer; 2020 Aug; 146():355-357. PubMed ID: 32553555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MAP2K1 K57N Conferred an Acquired Resistance to Furmonertinib, Dabrafenib and Trametinib Combined Therapy in Advanced Lung Adenocarcinoma with EGFR Mutation and BRAF V600E.
    Tan X; Wu Z; Chen M
    Onco Targets Ther; 2024; 17():307-312. PubMed ID: 38617091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.
    Vojnic M; Kubota D; Kurzatkowski C; Offin M; Suzawa K; Benayed R; Schoenfeld AJ; Plodkowski AJ; Poirier JT; Rudin CM; Kris MG; Rosen NX; Yu HA; Riely GJ; Arcila ME; Somwar R; Ladanyi M
    J Thorac Oncol; 2019 May; 14(5):802-815. PubMed ID: 30831205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Durable Clinical Response of Advanced Lung Adenocarcinoma Harboring
    Ding H; Zhuang Z; Xie J; Huang H; Tao Z; Liu Z
    Onco Targets Ther; 2020; 13():7933-7939. PubMed ID: 32848419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The MEK/ERK/miR-21 Signaling Is Critical in Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer Cells.
    Huang WC; Yadav VK; Cheng WH; Wang CH; Hsieh MS; Huang TY; Lin SF; Yeh CT; Kuo KT
    Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Characteristics, Co-Mutations, and Treatment Outcomes in Advanced Non-Small-Cell Lung Cancer Patients With the BRAF-V600E Mutation.
    Qu J; Shen Q; Li Y; Kalyani FS; Liu L; Zhou J; Zhou J
    Front Oncol; 2022; 12():911303. PubMed ID: 35814395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid and dramatic responses to dabrafenib and trametinib in BRAF V600E-mutated lung adenocarcinoma.
    Ota T; Okabayashi A; Fukuoka M
    Respirol Case Rep; 2021 Oct; 9(10):e0841. PubMed ID: 34484797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor response to EGFR/BRAF/MEK co-inhibition in a patient with EGFR mutated lung adenocarcinoma developing a BRAF
    Mauclet C; Collard P; Ghaye B; Hoton D; Nana FA
    Lung Cancer; 2021 Sep; 159():42-44. PubMed ID: 34304052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lung Cancer Driven by BRAF
    Huo KG; Notsuda H; Fang Z; Liu NF; Gebregiworgis T; Li Q; Pham NA; Li M; Liu N; Shepherd FA; Marshall CB; Ikura M; Moghal N; Tsao MS
    J Thorac Oncol; 2022 Feb; 17(2):277-288. PubMed ID: 34648945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
    Shea M; Costa DB; Rangachari D
    Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to the Combination of Osimertinib, Dabrafenib, and Trametinib in Leptomeningitis From
    Valet O; Swalduz A; Boussageon M; Buisson A; Avrillon V; Mastroïanni B; Pérol M
    JTO Clin Res Rep; 2021 Jun; 2(6):100192. PubMed ID: 34590033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient.
    Ribeiro MFSA; Knebel FH; Bettoni F; Saddi R; Sacardo KP; Canedo FSNA; Alessi JVM; Shimada AK; Marin JFG; Camargo AA; Katz A
    NPJ Precis Oncol; 2021 Feb; 5(1):5. PubMed ID: 33580193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promising Response to Dabrafenib Plus Trametinib in a Patient with Peritoneal Carcinomatosis from Non Small Lung Cancer Harboring
    Yagami Y; Nakahara Y; Manabe H; Yamamoto H; Otani S; Sato T; Igawa S; Kubota M; Sasaki J; Naoki K
    Onco Targets Ther; 2022; 15():1369-1374. PubMed ID: 36388158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclin-dependent kinase 4 upregulation mediates acquired resistance of dabrafenib plus trametinib in
    Hirai N; Hatanaka Y; Hatanaka KC; Uno Y; Chiba SI; Umekage Y; Minami Y; Okumura S; Ohsaki Y; Sasaki T
    Transl Lung Cancer Res; 2021 Sep; 10(9):3737-3744. PubMed ID: 34733624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.